Hepatitis C: cost of lost opportunities – Among the estimated 150 million people infected with hepatitis C virus, about 75 percent represent the poorest and most marginalized populations in middle income countries, where, stigma, poverty, and policies hinder access to both harm reduction prevention measures and then to treatment. While the costs of untreated infection include end-stage liver disease and cancer, the price of drugs serves as the greatest barrier to treatment. It is time, as this Lancet commentary puts it, to apply the lessons of HIV to hepatitis C, and approach the disease with respect for the value of health and other human rights.
Hepatitis C cure too expensive in Malaysia – This sums up how strange it is to have a deadly illness go untreated when a cure exists but is priced out of reach for people who need it.
TPP text confirms deadly impact on access to medicines in Malaysia – And this tells why the situation may not improve. But then again . . .
Obama’s trade deal is in trouble – This look at who does and doesn’t like the trade deal that global health treatment access advocates have said threatens access to lifesaving medicines is interesting, particularly where it explains why big pharmaceutical companies weren’t pleased. They wanted more.
MPP expands mandate to hepatitis C and tuberculosis treatment – The Medicines Patent Pool announces here that it will use the model it has used to widen access to HIV treatment to help make hepatitis C treatment affordable.
The need for a global health ethic – This Lancet commentary quotes conservationist Aldo Leopold saying “a system of conservation based solely on economic self interest is hopelessly lopsided,” and suggests the same is true of an approach to global health. What if, instead, a global health ethic recognized “the inherent interdependency of health”?